Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Day

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Trials|January 20, 2021
Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS projectNikki Totton, Steven Julious, Dyfrig Hughes, et al.
Pharmaceutical Statistics|January 12, 2018
Approaches to sample size calculation for clinical trials in rare diseasesFrank Miller, Sarah Zohar, Nigel Stallard, et al.
Nature Reviews. Drug Discovery|October 23, 2023
IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseasesAnneliene Hechtelt Jonker, Simon Day, Michela Gabaldo, et al.
Nature Reviews. Drug Discovery|April 22, 2020
Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development GuidebookAnneliene Hechtelt Jonker, Virginie Hivert, Michela Gabaldo, et al.
Orphanet Journal of Rare Diseases|March 4, 2017
Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.govSiew Wan Hee, Adrian Willis, Catrin Tudur Smith, et al.
Orphanet Journal of Rare Diseases|November 8, 2018
Recommendations for the design of small population clinical trialsSimon Day, Anneliene Hechtelt Jonker, Lilian Pek Lian Lau, et al.
Health Technology Assessment (Winchester, England)|November 20, 2023
Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshopNikki Totton, Steven A Julious, Elizabeth Coates, et al.
Clinical Trials (London, England)|December 6, 2014
The impact of registration of clinical trials units: the UK experienceEleanor McFadden, Saeeda Bashir, Steve Canham, et al.
British Journal of Clinical Pharmacology|October 26, 2021
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paperBeate Aurich, Dina Apele-Freimane, Tobias Banaschewski, et al.
JAMA|December 21, 2017
Guidelines for the Content of Statistical Analysis Plans in Clinical TrialsCarrol Gamble, Ashma Krishan, Deborah Stocken, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Trials|January 20, 2021
Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS projectNikki Totton, Steven Julious, Dyfrig Hughes, et al.
Pharmaceutical Statistics|January 12, 2018
Approaches to sample size calculation for clinical trials in rare diseasesFrank Miller, Sarah Zohar, Nigel Stallard, et al.
Nature Reviews. Drug Discovery|October 23, 2023
IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseasesAnneliene Hechtelt Jonker, Simon Day, Michela Gabaldo, et al.
Nature Reviews. Drug Discovery|April 22, 2020
Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development GuidebookAnneliene Hechtelt Jonker, Virginie Hivert, Michela Gabaldo, et al.
Orphanet Journal of Rare Diseases|March 4, 2017
Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.govSiew Wan Hee, Adrian Willis, Catrin Tudur Smith, et al.
Orphanet Journal of Rare Diseases|November 8, 2018
Recommendations for the design of small population clinical trialsSimon Day, Anneliene Hechtelt Jonker, Lilian Pek Lian Lau, et al.
Health Technology Assessment (Winchester, England)|November 20, 2023
Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshopNikki Totton, Steven A Julious, Elizabeth Coates, et al.
Clinical Trials (London, England)|December 6, 2014
The impact of registration of clinical trials units: the UK experienceEleanor McFadden, Saeeda Bashir, Steve Canham, et al.
British Journal of Clinical Pharmacology|October 26, 2021
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paperBeate Aurich, Dina Apele-Freimane, Tobias Banaschewski, et al.
JAMA|December 21, 2017
Guidelines for the Content of Statistical Analysis Plans in Clinical TrialsCarrol Gamble, Ashma Krishan, Deborah Stocken, et al.
Pageof 5